2019 KASL临床实践指南:慢性乙型肝炎的管理

2019-06-12 韩国肝脏病研究学会 Clin Mol Hepatol. 2019 Jun 12.

2019年6月,韩国肝脏病研究学会(KASL)发布了慢性乙型肝炎的管理指南,最初的KASL慢性乙型肝炎管理指南于2004年发布,并分别于2007年,2011年和2015年进行修订,本文的主要目的是为临床医生提供关于慢性丙肝患者管理的有用的临床信息和医学指南。

中文标题:

2019 KASL临床实践指南:慢性乙型肝炎的管理

英文标题:

KASL clinical practice guidelines for management of chronic hepatitis B.

发布机构:

韩国肝脏病研究学会

发布日期:

2019-06-12

简要介绍:

2019年6月,韩国肝脏病研究学会(KASL)发布了慢性乙型肝炎的管理指南,最初的KASL慢性乙型肝炎管理指南于2004年发布,并分别于2007年,2011年和2015年进行修订,本文的主要目的是为临床医生提供关于慢性丙肝患者管理的有用的临床信息和医学指南。 

拓展指南:乙型肝炎相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2019 KASL临床实践指南:慢性乙型肝炎的管理)] GetToolGuiderByIdResponse(projectId=1, id=d5da61c001ea940f, title=2019 KASL临床实践指南:慢性乙型肝炎的管理, enTitle=KASL clinical practice guidelines for management of chronic hepatitis B., guiderFrom=Clin Mol Hepatol. 2019 Jun 12., authorId=null, author=, summary=2019年6月,韩国肝脏病研究学会(KASL)发布了慢性乙型肝炎的管理指南,最初的KASL慢性乙型肝炎管理指南于2004年发布,并分别于2007年,2011年和2015年进行修订,本文的主要目的是为临床医生提供关于慢性丙肝患者管理的有用的临床信息和医学指南。 , cover=, journalId=null, articlesId=null, associationId=783, associationName=韩国肝脏病研究学会, associationIntro=null, copyright=0, guiderPublishedTime=Wed Jun 12 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<div>2019年6月,韩国肝脏病研究学会(KASL)发布了慢性乙型肝炎的管理指南,最初的KASL慢性乙型肝炎管理指南于2004年发布,并分别于2007年,2011年和2015年进行修订,本文的主要目的是为临床医生提供关于慢性丙肝患者管理的有用的临床信息和医学指南。 </div> <div><br> </div>拓展指南:<strong>与<font color=red>乙型肝炎</font>相关指南:</strong><br><ul><li><a href="https://www.medsci.cn/guideline/show_article.do?id=a4efe1c0016e729b" title="2018 台湾共识声明:慢性乙型肝炎的管理" target=_blank>2018 台湾共识声明:慢性乙型肝炎的管理</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=fa0401c0016106e5" title="2018美国肝病学会慢性乙型肝炎预防诊断及治疗指导意见解读" target=_blank>2018美国肝病学会慢性乙型肝炎预防诊断及治疗指导意见解读</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=ec1ae1c001592887" title="2018 共识报告:免疫抑制治疗和乙型肝炎再激活风险" target=_blank>2018 共识报告:免疫抑制治疗和乙型肝炎再激活风险</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=ef0751c001589234" title="《2018年亚裔美国人群慢性乙型肝炎管理专家共识》摘译" target=_blank>《2018年亚裔美国人群慢性乙型肝炎管理专家共识》摘译</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=d5f861c001586560" title="感染乙型肝炎病毒的育龄女性临床管理共识" target=_blank>感染乙型肝炎病毒的育龄女性临床管理共识</a></li> 更多信息请点击:<a href="https://www.medsci.cn/guideline/list.do?q=%E4%B9%99%E5%9E%8B%E8%82%9D%E7%82%8E" target=_blank>有关乙型肝炎更多指南</a></ul>, tagList=[TagDto(tagId=2629, tagName=慢性乙型肝炎)], categoryList=[CategoryDto(categoryId=9, categoryName=感染, tenant=100), CategoryDto(categoryId=22, categoryName=肝病, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5344, appHits=317, showAppHits=0, pcHits=3764, showPcHits=1792, likes=128, shares=5, comments=6, approvalStatus=1, publishedTime=Wed Jun 19 23:15:41 CST 2019, publishedTimeString=2019-06-12, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Wed Jun 19 23:15:41 CST 2019, updatedBy=null, updatedName=null, updatedTime=Wed Dec 27 19:54:00 CST 2023, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2019 KASL临床实践指南:慢性乙型肝炎的管理)])
2019 KASL临床实践指南:慢性乙型肝炎的管理
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=952965, encodeId=3f99952965d3, content=不错👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210718/fefe6467384e49b09c15bd5a914619d1/aa8483d54880438294f7e764334249cd.jpg, createdBy=e23e5270334, createdName=1481fa9cm89暂无昵称, createdTime=Wed Mar 31 23:29:04 CST 2021, time=2021-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951925, encodeId=d320951925dc, content=好指南, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e3f5293425, createdName=1486adbfm03暂无昵称, createdTime=Sun Mar 28 21:21:14 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951924, encodeId=5110951924ea, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e3f5293425, createdName=1486adbfm03暂无昵称, createdTime=Sun Mar 28 21:21:10 CST 2021, time=2021-03-28, status=1, ipAttribution=)]
    2021-03-31 1481fa9cm89暂无昵称

    不错👍

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=952965, encodeId=3f99952965d3, content=不错👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210718/fefe6467384e49b09c15bd5a914619d1/aa8483d54880438294f7e764334249cd.jpg, createdBy=e23e5270334, createdName=1481fa9cm89暂无昵称, createdTime=Wed Mar 31 23:29:04 CST 2021, time=2021-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951925, encodeId=d320951925dc, content=好指南, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e3f5293425, createdName=1486adbfm03暂无昵称, createdTime=Sun Mar 28 21:21:14 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951924, encodeId=5110951924ea, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e3f5293425, createdName=1486adbfm03暂无昵称, createdTime=Sun Mar 28 21:21:10 CST 2021, time=2021-03-28, status=1, ipAttribution=)]
    2021-03-28 1486adbfm03暂无昵称

    好指南

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=952965, encodeId=3f99952965d3, content=不错👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210718/fefe6467384e49b09c15bd5a914619d1/aa8483d54880438294f7e764334249cd.jpg, createdBy=e23e5270334, createdName=1481fa9cm89暂无昵称, createdTime=Wed Mar 31 23:29:04 CST 2021, time=2021-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951925, encodeId=d320951925dc, content=好指南, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e3f5293425, createdName=1486adbfm03暂无昵称, createdTime=Sun Mar 28 21:21:14 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951924, encodeId=5110951924ea, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e3f5293425, createdName=1486adbfm03暂无昵称, createdTime=Sun Mar 28 21:21:10 CST 2021, time=2021-03-28, status=1, ipAttribution=)]
    2021-03-28 1486adbfm03暂无昵称

    好文章

    0